Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
2.
Mol Med ; 18: 83-94, 2012 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-22033674

RESUMEN

Topoisomerase I is a privileged target for widely used anticancer agents such as irinotecan. Although these drugs are classically considered to be DNA-damaging agents, increasing evidence suggests that they might also influence the tumor environment. This study evaluates in vivo cellular and molecular modifications induced by irinotecan, a topoisomerase I-directed agent, in patient-derived colon tumors subcutaneously implanted in athymic nude mice. Irinotecan was given intraperitoneally at 40 mg/kg five times every 5 d, and expression profiles were evaluated at d 25 in tumors from treated and untreated animals. Unexpectedly, the in vivo antitumor activity of irinotecan was closely linked to a downregulation of hypoxia-inducible factor-1α (HIF1A) target genes along with an inhibition of HIF1A protein accumulation. The consequence was a decrease in tumor angiogenesis leading to tumor size stabilization. These results highlight the molecular basis for the antitumor activity of a widely used anticancer agent, and the method used opens the way for mechanistic studies of the in vivo activity of other anticancer therapies.


Asunto(s)
Antineoplásicos/uso terapéutico , Camptotecina/análogos & derivados , ADN-Topoisomerasas de Tipo I/metabolismo , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Neovascularización Patológica/tratamiento farmacológico , Inhibidores de Topoisomerasa I/uso terapéutico , Animales , Camptotecina/uso terapéutico , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Irinotecán , Masculino , Ratones , Ratones Desnudos , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Crit Care ; 14(5): R163, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20825636

RESUMEN

INTRODUCTION: The purpose of this study was to investigate the gene expression of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) in circulating mononuclear cells harvested from septic shock patients on drotrecogin-α activated (DAA) in order to determine whether this treatment has any effect on the inflammation phase. METHODS: We conducted a prospective cohort study in two intensive care departments. Blood samples were collected at inclusion (T1) and 36 hours later (T2) to measure plasma cytokines and the changes in intracellular TNF-α, IL-10 and IFN-γ mRNA expressions using the real-time quantitative polymerase chain reaction (RT-qPCR). Thirty-two septic shock patients were included: 16 with DAA at 24 µg/kg/h for 96 hours (DAA+) and 16 control (DAA-) eligible but contraindicated for DAA because of low platelet count. RESULTS: The basal characteristics were similar in both groups: mortality (50%), plasma cytokine concentrations, and baseline IFN-γ, TNF-α and IL-10 mRNA expressions (DAA+ vs. DAA-). At T2, there was a significant IFN-γ gene down-regulation in DAA+ but not in DAA- patients (-0.34 (-0.62; +1.54) vs. +1.41 (+0.35; +5.87), P = 0.008). In survivors, DAA administration was associated with a down-expression of both IFN-γ (-0.65 (-0.93; 0.48) vs. +0.7 (-0.04; +1.26), P = 0.01) and IL-10 (-0.78 (-0.92; -0.6) vs. -0.18 (-0.68; +0.46), P = 0.038). In the non-survivors, DAA infusion was associated with IL-10 over-expression when compared with survivors (+0.54 (-0.35; +11.52) vs. -0.78 (-0.92; -0.6), P < 0.001). CONCLUSIONS: In this study, lack of IL-10 gene down-expression despite a 36-hour infusion of DAA is an ominous sign in septic shock patients suggesting that DAA is not able to reverse the outcome. Our results suggest that DAA can decrease the expression of anti-inflammatory cytokines in septic shock patients. IL-10 or IFN-γ gene down-expression could represent markers of DAA response.


Asunto(s)
Regulación hacia Abajo/fisiología , Interleucina-10/antagonistas & inhibidores , Interleucina-10/genética , Leucocitos Mononucleares/metabolismo , Proteína C/administración & dosificación , Choque Séptico/sangre , Anciano , Estudios de Cohortes , Regulación hacia Abajo/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Infusiones Intravenosas , Interleucina-10/biosíntesis , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/patología , Persona de Mediana Edad , Proyectos Piloto , Estudios Prospectivos , Proteínas Recombinantes/administración & dosificación , Choque Séptico/tratamiento farmacológico , Choque Séptico/patología
4.
Clin Cancer Res ; 15(4): 1297-307, 2009 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-19190131

RESUMEN

PURPOSE: Despite recent progress, colon cancer is often resistant to combination chemotherapy, highlighting the need for development of novel therapeutic approaches. An attractive target is hypoxia-inducible factor-1alpha (HIF-1alpha), a key transcription factor with a pivotal role in tumor cell metabolism. One potential class of therapeutic agents targeting HIF-1alpha are mammalian target of rapamycin inhibitors such as rapamycin. A second class are topoisomerase I inhibitors, such as irinotecan, which are able to inhibit the accumulation of HIF-1alpha. We here investigated whether combination of rapamycin and irinotecan was active in human colon cancer models. EXPERIMENTAL DESIGN: Human metastatic tumors were xenografted in nude mice and treated with low doses of irinotecan alone, rapamycin alone, or combination of both drugs. The cellular effects of irinotecan and rapamycin were further characterized for HT-29 and HCT-116 colon cancer cells in vitro. RESULTS: In contrast to single-agent therapy, xenografted tumors treated with combination of irinotecan and rapamycin showed potent inhibition of the mammalian target of rapamycin/HIF-1alpha axis, which was accompanied by a dramatic reduction in tumor volume. In vitro experiments showed that exposure to low concentrations of the two drugs resulted in massive HT-29 cell death under hypoxic, but not normoxic, conditions, in full agreement with a cytotoxic effect mediated through HIF-1alpha rather than through induction of genotoxic lesions. HCT-116 cells were less sensitive to the combined treatment due to constitutive activation of phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways. CONCLUSION: These results identify HIF-1alpha as a promising target and provide a rationale for clinical trials of low-dose irinotecan and rapamycin combination toward metastatic colon cancer.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Camptotecina/análogos & derivados , Neoplasias del Colon/tratamiento farmacológico , Subunidad alfa del Factor 1 Inducible por Hipoxia/fisiología , Proteínas Quinasas/fisiología , Sirolimus/administración & dosificación , Animales , Camptotecina/administración & dosificación , Camptotecina/farmacología , Línea Celular Tumoral , Neoplasias del Colon/patología , Glucólisis/efectos de los fármacos , Humanos , Irinotecán , Sistema de Señalización de MAP Quinasas , Masculino , Ratones , Fosfatidilinositol 3-Quinasas/fisiología , Proteínas Proto-Oncogénicas c-akt/fisiología , Sirolimus/farmacología , Serina-Treonina Quinasas TOR , Proteína p53 Supresora de Tumor/fisiología , Ensayos Antitumor por Modelo de Xenoinjerto
5.
Dig Dis Sci ; 54(10): 2084-93, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19051021

RESUMEN

Crohn's disease is considered to be caused either by an excess of T-cell effector functions and/or by a defective regulatory T-cell compartment. The aim of this study was to assess in Crohn's disease the frequency of circulating CD4(+)CD25(high) T cells that possess regulatory T-cell functions and CD4(+)CD25(low) T cells that contain activated T cells. Flow cytometry of peripheral blood was used to assess CD4(+)CD25(high) and CD4(+)CD25(low) T-cell frequencies in a cohort of 66 patients with Crohn's disease in comparison to 19 patients with ulcerative colitis and 31 healthy individuals enrolled as controls. The CD4(+)CD25(high) T-cell frequency was significantly lowered in naïve Crohn's disease (P = 0.013) and in ulcerative colitis (P = 0.001). CD4(+)CD25(low) T-cell frequency was increased in Crohn's disease (P = 0.0001) and in ulcerative colitis (P = 0.0002). Both CD4(+)CD25(high) and CD4(+)CD25(low) T-cell frequencies are altered in naïve Crohn's disease resulting in an imbalance between both populations and a relative contraction of the CD4(+)CD25(high) T-cell population.


Asunto(s)
Antígenos CD4/sangre , Enfermedad de Crohn/inmunología , Subunidad alfa del Receptor de Interleucina-2/sangre , Linfocitos T Reguladores , Adulto , Anciano , Recuento de Células Sanguíneas , Colitis Ulcerosa/sangre , Colitis Ulcerosa/inmunología , Enfermedad de Crohn/sangre , Femenino , Citometría de Flujo , Humanos , Subgrupos Linfocitarios/inmunología , Masculino , Persona de Mediana Edad
6.
Artículo en Inglés | MEDLINE | ID: mdl-18931436

RESUMEN

Human UHRF1 belongs to the unique mammalian family of proteins which contain a SET- and RING finger-associated (SRA) domain. This 180-residue domain has been reported to play key roles in the functions of the protein. It allows UHRF1 to bind methylated DNA, histone deacetylase 1 and DNA methyltransferase 1, suggesting a bridge between DNA methylation and the histone code. No structural data is available for any SRA domain. Native and SeMet-labelled SRA domains of human UHRF1 were overexpressed in Escherichia coli cells, purified to homogeneity and crystallized using the hanging-drop vapour-diffusion method. A complete MAD data set was collected to 2.2 A resolution at 100 K. Crystals of the SeMet-labelled protein belonged to the trigonal space group P3(2)21, with unit-cell parameters a = b = 53.78, c = 162.05 A.


Asunto(s)
Proteínas Potenciadoras de Unión a CCAAT/química , Proteínas Potenciadoras de Unión a CCAAT/metabolismo , Cristalización , Cristalografía/métodos , ADN/metabolismo , Metilación de ADN , Histona Desacetilasas/metabolismo , Histonas/metabolismo , Humanos , Fragmentos de Péptidos/química , Fragmentos de Péptidos/aislamiento & purificación , Unión Proteica , Ubiquitina-Proteína Ligasas
7.
Toxicol In Vitro ; 40: 1-10, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27979589

RESUMEN

Benzene is extensively used in industry despite its leukemogenic activity, representing a significant occupational hazard. We investigated if long-term treatment with low-doses hydroquinone (HQ), a benzene metabolite, might be sufficient to alter in vitro the epigenetic signature underlining LINE-1 sequences, a poorly explored step in health risks associated with benzene exposure. In HL-60 cell line, exploring the epigenetic events occurring in chromatin, we found the transient instauration of the distinctive signature combining the repressive H3Lys27 tri-methylation mark and the activating H3Lys4 tri-methylation mark (H3K27me3/H3K4me3), indicating a tendency toward a poised chromatin conformation. These alterations are lost in time after short-term treatments, while the long-term setting, performed using a concentration within the levels of total HQ in peripheral blood of benzene-exposed workers, showed a gradual increase in H3K4me3. We observed the absence of statistically significant variations in DNA methylation and expression levels of LINE-1, despite a decrease in protein levels of UHRF1, DNA methyl-transferases and histone methyl-transferases. In conclusion, in vitro treatment with low-dose HQ determined the instauration of a reversible poised state of chromatin in LINE-1 sequences, suggesting that prolonged exposure could cause persistent epigenetic alterations.


Asunto(s)
Hidroquinonas/toxicidad , Elementos de Nucleótido Esparcido Largo/efectos de los fármacos , Proteínas Potenciadoras de Unión a CCAAT/metabolismo , Supervivencia Celular/efectos de los fármacos , Cromatina/metabolismo , Metilación de ADN/efectos de los fármacos , Epigénesis Genética/efectos de los fármacos , Células HL-60 , Histonas/metabolismo , Humanos , Metiltransferasas/metabolismo , Ubiquitina-Proteína Ligasas
8.
J Clin Oncol ; 23(10): 2248-55, 2005 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-15800315

RESUMEN

PURPOSE: Since the recent development of biologic agents targeting oncogenes, increasing attention has been focused on determining the role of tyrosine kinase receptors in the pathogenesis of tumors. Our study was designed to investigate the status of region 4q12, which contains the candidate gene c-kit, and the expression of c-kit by immunohistochemistry (IHC). PATIENTS AND METHODS: Paired blood and biopsy specimens of 68 children treated for high-grade primary osteosarcomas were collected. Microsatellite analysis at two genomic sites containing c-kit gene was performed on paired DNA using a sensible fluorescent polymerase chain reaction technology. To confirm the DNA data, we studied c-kit protein expression by IHC in 56 available paraffin-embedded tumor tissues. RESULTS: The frequency of allelic imbalance (AI) at locus 4q12 was 39% in the overall population. In agreement with previous studies, we did not detect microsatellite instability, allowing us to hypothesize that this pathway is not implicated. Furthermore, the normal status at locus 4q12 was associated with a significantly better survival in the whole osteosarcoma population (P = .05). IHC overexpression of c-kit was concordant in all cases presenting an AI. However, normal status at locus 4q12 was correlated to an absence of c-kit protein expression in 19 (65.5%) of 29 informative cases. CONCLUSION: Allelotyping of locus 4q12, which contains the c-kit gene, could help pediatric osteosarcoma prognostic screening and showed a strong correlation with overexpression of c-kit protein. These results allowed us to hypothesize that, in some cases, a mutation of c-kit gene could lead to a protein overexpression.


Asunto(s)
Desequilibrio Alélico , Neoplasias Óseas/genética , Cromosomas Humanos Par 4 , Perfilación de la Expresión Génica , Osteosarcoma/genética , Proteínas Proto-Oncogénicas c-kit/biosíntesis , Proteínas Proto-Oncogénicas c-kit/genética , Adolescente , Adulto , Neoplasias Óseas/patología , Niño , Preescolar , Estudios de Cohortes , Análisis Mutacional de ADN , ADN de Neoplasias/genética , Femenino , Humanos , Inmunohistoquímica , Masculino , Osteosarcoma/patología , Reacción en Cadena de la Polimerasa , Pronóstico , Análisis de Supervivencia
9.
Prog Urol ; 16(4): 429-34, 2006 Sep.
Artículo en Francés | MEDLINE | ID: mdl-17069034

RESUMEN

OBJECTIVE: To detect the presence of tumour DNA in urine of patients with renal cancer based on microsatellite analysis. MATERIAL AND METHOD: Blinded, comparative, experimental study conducted between July 1996 and December 2003. Preoperative urine and blood samples were collected from 69 patients with renal cancer (pT1 to pT4). The control population comprised 35 patients with a benign urological disease. Loss of heterozygosity (LOH) and allele amplification were investigated by analysing allele imbalances between urinary DNA and blood lymphocyte DNA. Twenty-six loci were analysed, including 23 microsatellites. We studied the sensitivity and specificity of this analysis as a function of stage, grade and invasion of renal cavities by the tumour. RESULTS: The sensitivity of the test was 61% for pT1a and the global sensitivity was 62.3%. A significant difference was observed in favour of low nuclear grades (p < 0.05). More than 80% of tumours detected were identified by 4 microsatellites. The specificity was 83%. Renal cavities were invaded by the tumour in 38% of cases. No correlation was observed between invasion of renal cavities and the result of the test. CONCLUSION: The results are encouraging, particularly for small tumours and justify development of clinical applications.


Asunto(s)
ADN de Neoplasias/orina , Neoplasias Renales/diagnóstico , Neoplasias Renales/orina , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Repeticiones de Microsatélite , Persona de Mediana Edad , Sensibilidad y Especificidad
10.
J Virol Methods ; 229: 60-5, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26721377

RESUMEN

Biobanking or collection and storage of specimens for future research purposes have become an essential tool in many fields of biomedical research and aims to provide a better understanding of disease mechanisms as well as the identification of disease-specific biomarkers that can navigate in complex diseases. In this study, we assessed the use of Flinders Technology Associates (FTA) cards as a long-term storage device for cervical specimens with suspected human papillomavirus (HPV) infections. HPV detection and genotyping results in liquid-based transport media were compared to HPV results from FTA cards. The overall agreement for the presence of any HPV infection between liquid-based medium and FTA cards stored for 1 year at ambient temperature was 100%. Reproducibility analysis of HPV detection and genotyping from FTA cards demonstrated that FTA cards are a reliable medium to store and preserve viral nucleic acids. Biobanking of cervical cells on FTA cards may provide a key resource for epidemiological and retrospective HPV studies.


Asunto(s)
Técnicas Citológicas/métodos , ADN Viral/aislamiento & purificación , Papillomaviridae/aislamiento & purificación , Preservación Biológica/métodos , Manejo de Especímenes/métodos , Virología/métodos , Adulto , Anciano , Cuello del Útero/virología , ADN Viral/genética , Femenino , Técnicas de Genotipaje/métodos , Humanos , Persona de Mediana Edad , Papillomaviridae/genética , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/virología , Reproducibilidad de los Resultados , Estudios Retrospectivos , Adulto Joven
11.
Oncogene ; 22(39): 7913-21, 2003 Sep 11.
Artículo en Inglés | MEDLINE | ID: mdl-12970739

RESUMEN

The Cdx1 homeobox gene encodes an intestine-specific transcription factor with a pro-oncogenic function in vitro. Here we have analysed the pattern of Cdx1 in human colon cancer progression. Cdx1 expression remains at a high level in the majority of the polyps and it is even overexpressed in more than one-third of the specimens, consistent with the fact that the gene is an intestine-specific target of oncogenic pathways. However, Cdx1 decreases in one-fifth of the polyps, which is reminiscent of the loss of expression previously reported in the majority of carcinomas. Allelic imbalance analysis demonstrates that the Cdx1 locus located on chromosome 5q is a major site of genomic rearrangement in colorectal cancers, and that the frequency of the rearrangements increases during polyps to carcinoma progression. Allelic imbalance at the Cdx1 locus occurs in relation to, although not invariably in association with, the rearrangements at the APC locus on the same chromosomal arm. Xenografts of primary human colon carcinomas indicate that the level of Cdx1 mRNA correlates with the intensity of allelic imbalance. Together, these data show that Cdx1 exhibits a complex pattern during colorectal cancer progression. Given that Cdx1 has a pro-oncogenic function in vitro, the maintenance of a high level of expression in polyps, and even its overexpression in one-third of the specimens, suggest that this homeobox gene may be an important factor in the process toward malignant transformation during the first steps of tumorigenesis.


Asunto(s)
Carcinoma/genética , Neoplasias del Colon/genética , Pólipos del Colon/genética , Proteínas de Homeodominio/genética , Pólipos Intestinales/genética , Proteína de la Poliposis Adenomatosa del Colon/genética , Alelos , Desequilibrio Alélico/genética , Secuencia de Aminoácidos , Animales , Carcinoma/patología , Cromosomas Humanos Par 5/genética , Neoplasias del Colon/patología , Pólipos del Colon/patología , Progresión de la Enfermedad , Regulación de la Expresión Génica , Reordenamiento Génico , Proteínas de Homeodominio/metabolismo , Humanos , Pólipos Intestinales/patología , Neoplasias Hepáticas/secundario , Ratones , Ratones Desnudos , Datos de Secuencia Molecular , Trasplante de Neoplasias , Trasplante Heterólogo
13.
Intensive Care Med ; 30(3): 408-15, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-14722631

RESUMEN

OBJECTIVE: To assess the levels of expression of the antiapoptotic gene Bcl-2 and the proapoptotic gene Bax in circulating mononuclear cells (CMNC) harvested during the course of severe sepsis (SS) in formerly non-immunocompromised patients undergoing hospital-acquired infection, in parallel to cytokine levels. DESIGN: Prospective study. SETTING: Intensive care unit. PARTICIPANTS: A total of 24 patients without immunodeficiency undergoing standard goal-directed therapy for nosocomial SS, 10 critically ill patients without sepsis, and 10 healthy controls. INTERVENTIONS: Blood was collected before infection and within 12 h, 1, 3 and 7 days after fever onset, to determine plasma concentrations of IL-6, IL-10, TNF-alpha, C-reactive protein, whole blood cell counts, lymphocyte subsets, annexin V labelling for apoptosis, and Bax and Bcl-2 relative RNA expression by real-time polymerase chain reaction. RESULTS: SS patients displayed increased cytokine concentrations, TNF-alpha being significantly increased at full-blown sepsis. Within 12 h after onset of infection, lymphocyte counts were lower in SS patients than in critically ill controls ( p=0.001), and this phenomenon was marked in CD4+ and CD8+ subsets ( p<0.001). This was associated with enhanced apoptosis in CMNC (15.7+/-8.7% vs 3.4+/-2.1%, p<0.001) and a significant down-expression of the Bcl-2 gene throughout the study ( p<0.05). In contrast, the expression of Bax did not change significantly. Within 12 h of fever onset, non-survivors expressed a 10-fold down-expression of Bcl-2 when compared to survivors ( p<0.001). CONCLUSIONS: An early transient down-expression of the gene Bcl-2 occurred in CMNC harvested from SS patients who died despite intensive care. In contrast, the expression of the gene Bax did not change significantly.


Asunto(s)
Regulación hacia Abajo , Expresión Génica , Genes bcl-2 , Proteínas Proto-Oncogénicas c-bcl-2 , Síndrome de Respuesta Inflamatoria Sistémica/genética , Análisis de Varianza , Apoptosis/genética , Estudios de Casos y Controles , Citocinas/sangre , Femenino , Humanos , Leucocitos Mononucleares/metabolismo , Subgrupos Linfocitarios/metabolismo , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Proteínas Proto-Oncogénicas/genética , Estadísticas no Paramétricas , Proteína X Asociada a bcl-2
14.
Anticancer Res ; 22(6A): 3165-70, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12530060

RESUMEN

We have recently identified ICBP90 as being a protein able to bind in vitro a CCAAT box of the topoisomerase II alpha gene promoter. The aim of the present work was to check whether ICBP90 is able to regulate in vivo topoisomerase II alpha expression in human lung fibroblasts under various proliferating conditions. Transient transfection experiments performed on moderately growing human lung fibroblasts (50% of confluence) showed that overexpression of ICBP90 is associated with an elevation of topoisomerase II alpha expression and an increase of the cell proliferation rate. In highly proliferating human lung fibroblasts (20% confluence) overexpression of ICBP90 had no effect. In contrast, in non-proliferating fibroblasts (100% confluence) overexpression of ICBP90 allowed recovery of topoisomerase II alpha expression levels with a concomitant overgrowth of confluent cell cultures. Our results show that ICBP90 regulates topoisomerase II alpha expression and is able to overcome cell contact inhibition signaling, suggesting that increased ICBP90 expression may be involved in carcinogenesis.


Asunto(s)
Proteínas Potenciadoras de Unión a CCAAT/fisiología , Inhibición de Contacto/fisiología , ADN-Topoisomerasas de Tipo II/biosíntesis , Antígenos de Neoplasias , Proteínas Potenciadoras de Unión a CCAAT/biosíntesis , Proteínas Potenciadoras de Unión a CCAAT/genética , División Celular/genética , División Celular/fisiología , Células Cultivadas , Inhibición de Contacto/genética , ADN-Topoisomerasas de Tipo II/genética , Proteínas de Unión al ADN , Inducción Enzimática , Fibroblastos/citología , Fibroblastos/enzimología , Fibroblastos/fisiología , Regulación Enzimológica de la Expresión Génica/genética , Regulación Enzimológica de la Expresión Génica/fisiología , Células HeLa , Humanos , Pulmón/citología , Pulmón/enzimología , Pulmón/fisiología , Plásmidos/genética , Regiones Promotoras Genéticas , Transfección/métodos , Ubiquitina-Proteína Ligasas
15.
Bull Acad Natl Med ; 187(5): 847-60; discussion 861, 2003.
Artículo en Francés | MEDLINE | ID: mdl-14979051

RESUMEN

Systematic allelotyping of colorectal cancers and liver metastases is realized since 1996 in a close collaboration between the surgery, pathology departments and the molecular biology laboratory. Using amplification of 35 different microsatellites allelic imbalances and microsatellites instabilities were recorded. Beside the well documented increasing amount of genomic rearrangements we identified a subset of early stages tumors presenting a profile of rearrangement corresponding to high grades, and high grades cancers with a molecular profile corresponding to low grade. The comparison of synchrones liver metastases and colorectal tumors allowed us to propose for a more extensive studies the existence of sensitive structural chromosomic regions affecting separately both chromosomes and that it should be possible to identify a limited number of specific genes concerned by most of the advanced stages.


Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma/secundario , Neoplasias Colorrectales/patología , Neoplasias Hepáticas/secundario , Desequilibrio Alélico , Biomarcadores de Tumor/genética , Carcinoma/química , Carcinoma/genética , Inestabilidad Cromosómica , Aberraciones Cromosómicas , Células Clonales/química , Células Clonales/patología , Neoplasias Colorrectales/genética , ADN de Neoplasias/genética , Genes Supresores de Tumor , Humanos , Neoplasias Hepáticas/química , Neoplasias Hepáticas/genética , Repeticiones de Microsatélite , Proteínas de Neoplasias/genética , Oncogenes , Pronóstico
16.
PLoS One ; 7(5): e36766, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22574222

RESUMEN

Previous studies have shown that DNA can be transferred from dying engineered cells to neighboring cells through the phagocytosis of apoptotic bodies, which leads to cellular transformation. Here, we provide evidence of an uptake of apoptotic-derived cervical cancer cells by human mesenchymal cells. Interestingly, HeLa (HPV 18+) or Ca Ski (HPV16+) cells, harboring integrated high-risk HPV DNA but not C-33 A cells (HPV-), were able to transform the recipient cells. Human primary fibroblasts engulfed the apoptotic bodies effectively within 30 minutes after co-cultivation. This mechanism is active and involves the actin cytoskeleton. In situ hybridization of transformed fibroblasts revealed the presence of HPV DNA in the nucleus of a subset of phagocytosing cells. These cells expressed the HPV16/18 E6 gene, which contributes to the disruption of the p53/p21 pathway, and the cells exhibited a tumorigenic phenotype, including an increased proliferation rate, polyploidy and anchorage independence growth. Such horizontal transfer of viral oncogenes to surrounding cells that lack receptors for HPV could facilitate the persistence of the virus, the main risk factor for cervical cancer development. This process might contribute to HPV-associated disease progression in vivo.


Asunto(s)
Apoptosis , Transformación Celular Viral , Papillomaviridae/fisiología , Neoplasias del Cuello Uterino/patología , Proliferación Celular , Transformación Celular Viral/genética , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/metabolismo , Femenino , Fibroblastos/citología , Genes Virales/genética , Células HeLa , Humanos , Mesodermo/citología , Oncogenes/genética , Papillomaviridae/genética , Poliploidía , Transducción de Señal , Proteína p53 Supresora de Tumor/metabolismo
17.
Hum Pathol ; 42(2): 244-53, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21238786

RESUMEN

Colon carcinogenesis encompasses the stepwise accumulation of genomic aberrations correlated with the transition of aberrant crypt-adenoma-carcinoma. Recent data have revealed that, in addition to the microsatellite-instable phenotype, the chromosome instability pathway, representing four fifth of the colon carcinoma, could be involved in heterogeneous molecular alterations. Our project was aimed at determining the existence of distinct molecular subtypes in 159 non-microsatellite-instable colon polyps and their correlation with histology and dysplasia, using allelotyping, MGMT promoter gene methylation status, and K-RAS mutation analyses. Allelic imbalance, MGMT methylation, and K-RAS mutations arise in 62%, 39%, and 32% of polyps, respectively. Only 14% of polyps had no alterations. A 2-way hierarchical clustering analysis of the allelic imbalances identified subgroups of polyps according to their allelic imbalance frequency and distribution. Not only tubulovillous adenoma but also high-grade adenomas were correlated with high global allelic imbalance frequency (P = .005 and P = .003), with allelic imbalance at microsatellites targeting chromosomes 1, 6, and 9. In conclusion, the data presented in this study show that a large heterogeneity exists in the molecular patterns of alterations in precancerous colon lesions, favoring different modes of tumor initiation. Therefore, molecular alterations correlated with tubulovillous-type and high-grade dysplasia could represent targets identifying predictive factors of progression.


Asunto(s)
Adenoma/genética , Neoplasias del Colon/genética , Pólipos del Colon/genética , Inestabilidad de Microsatélites , Adenoma/patología , Anciano , Desequilibrio Alélico , Neoplasias del Colon/patología , Pólipos del Colon/patología , Islas de CpG/genética , Metilación de ADN , Metilasas de Modificación del ADN/genética , Enzimas Reparadoras del ADN/genética , ADN de Neoplasias/análisis , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Proteínas Supresoras de Tumor/genética
18.
J Thorac Oncol ; 3(4): 331-9, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18379349

RESUMEN

INTRODUCTION: Recent clinical success of epidermal growth factor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) have raised hopes that targeting other deregulated growth factor signaling, such as the hepatocyte growth factor/MET pathway, will lead to new therapeutic options for NSCLC. Furthermore, NSCLC present secondary EGFR-TKIs resistance related to exons 20 and 19 EGFR mutations or more recently to MET amplification. The aim of this study was to determine MET copy number related to EGFR copy number and K-Ras mutations in a targeted TKI naive NSCLC cohort. METHODS: We investigated 106 frozen tumors from surgically resected NSCLC patients. Genes copy number of MET and EGFR were assessed by quantitative relative real-time polymerase chain reaction and K-Ras mutations by sequencing. RESULTS: MET is amplified in 22 cases (21%) and deleted in nine cases (8.5%). EGFR is amplified in 31 cases (29%). K-Ras is mutated in 11 cases (10.5%). As observed for EGFR amplification, MET amplification is never associated with K-Ras mutation. MET amplification could be associated with EGFR amplification. MET amplification is not related to clinical and pathologic features. MET amplification and EGFR amplification showed a trend toward poor prognosis in adenocarcinomas. CONCLUSION: In EGFR-TKIs naive NSCLC patients, MET amplification is a frequent event, which could be associated with EGFR amplification, but not with K-Ras mutation. MET amplification may identify a subset of NSCLC for new targeted therapy. It will also be important to evaluate MET copy number to properly interpret future clinical trials.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/genética , Dosificación de Gen , Neoplasias Pulmonares/genética , Proteínas Proto-Oncogénicas/genética , Receptores de Factores de Crecimiento/genética , Adenocarcinoma/genética , Adenocarcinoma/secundario , Adenocarcinoma/cirugía , Adenocarcinoma Bronquioloalveolar/genética , Adenocarcinoma Bronquioloalveolar/secundario , Adenocarcinoma Bronquioloalveolar/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Pulmón de Células no Pequeñas/cirugía , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/secundario , Carcinoma de Células Escamosas/cirugía , Estudios de Cohortes , Análisis Mutacional de ADN , Receptores ErbB/genética , Femenino , Humanos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Pronóstico , Proteínas Proto-Oncogénicas c-met , Proteínas Proto-Oncogénicas p21(ras) , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Tasa de Supervivencia , Proteínas ras/genética
19.
Mol Biol Cell ; 19(8): 3554-63, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18508923

RESUMEN

Heterochromatic chromosomal regions undergo large-scale reorganization and progressively aggregate, forming chromocenters. These are dynamic structures that rapidly adapt to various stimuli that influence gene expression patterns, cell cycle progression, and differentiation. Np95-ICBP90 (m- and h-UHRF1) is a histone-binding protein expressed only in proliferating cells. During pericentromeric heterochromatin (PH) replication, Np95 specifically relocalizes to chromocenters where it highly concentrates in the replication factories that correspond to less compacted DNA. Np95 recruits HDAC and DNMT1 to PH and depletion of Np95 impairs PH replication. Here we show that Np95 causes large-scale modifications of chromocenters independently from the H3:K9 and H4:K20 trimethylation pathways, from the expression levels of HP1, from DNA methylation and from the cell cycle. The PHD domain is essential to induce this effect. The PHD domain is also required in vitro to increase access of a restriction enzyme to DNA packaged into nucleosomal arrays. We propose that the PHD domain of Np95-ICBP90 contributes to the opening and/or stabilization of dense chromocenter structures to support the recruitment of modifying enzymes, like HDAC and DNMT1, required for the replication and formation of PH.


Asunto(s)
Proteínas Potenciadoras de Unión a CCAAT/fisiología , Centrómero/ultraestructura , Heterocromatina/fisiología , Acetilación , Animales , Ciclo Celular , Cromatina/química , Metilación de ADN , Heterocromatina/química , Histonas/química , Ratones , Modelos Biológicos , Células 3T3 NIH , Nucleosomas/metabolismo , Estructura Terciaria de Proteína , Interferencia de ARN , Ubiquitina-Proteína Ligasas
20.
Crit Care Med ; 35(1): 69-75, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17133181

RESUMEN

OBJECTIVE: Drotrecogin alpha (activated) (DAA), or recombinant human activated protein C, is a new treatment in sepsis-induced multiple organ failure, leading to significant reduction in the mortality rate, thanks to its anticoagulant properties. It has been suggested that DAA has anti-inflammatory and antiapoptotic effects in sepsis animal models. This study investigates the potential actions of DAA on circulating mononuclear cells apoptosis in human septic shock. DESIGN: Prospective, cohort study. SETTING: Two intensive care wards and two research laboratories in a university hospital. PATIENTS: Twenty-two septic shock patients with DAA treatment (DAA+), 19 septic shock patients without DAA treatment (DAA-), and 14 healthy controls were successively enrolled, but only 20 DAA+ and 16 DAA- patients fulfilled criteria for statistical analysis. INTERVENTIONS: Blood samples were collected at inclusion and 24 hrs later. MEASUREMENTS AND MAIN RESULTS: Circulating mononuclear cell apoptosis levels were assessed by flow cytometry with annexin V, and variations of the apoptotic rheostats (Bax/Bcl-2 and Bax/Bcl-xl ratios) were analyzed by real-time reverse transcription-polymerase chain reaction. Apoptosis was significantly increased in septic shock patients (DAA+, 12 +/- 6.4%; DAA-, 10.4 +/- 5%) vs. healthy patients (3.4 +/- 2.1%, p < .001). Twenty-four hours after DAA infusion, apoptosis was significantly lower in the DAA+ group compared with DAA- ones (respectively, 11.7 +/- 5.3% and 16.2 +/- 7.6%, p < .001). At inclusion, DAA+ and DAA- groups showed comparable Bax/Bcl-2 ratio (DAA+, 0.92 +/- 0.9; DAA-, 1.32 +/- 0.87) and Bax/Bcl-xl ratio (DAA+, 2 +/- 1.04; DAA-, 1.31 +/- 0.93). In contrast, 24 hrs later we observed a significant decrease in these ratios, indicating an antiapoptotic effect in the DAA+ group (Bax/Bcl-2, 0.39 +/- 0.27; Bax/Bcl-xl, 0.68 +/- 0.35) compared with the DAA- group (Bax/Bcl-2, 1.81 +/- 1.1; Bax/Bcl-xl, 1.22 +/- 0.92, p = .001 and p = .039, respectively). CONCLUSIONS: In vivo, in human septic shock, DAA has antiapoptotic effects on circulating mononuclear cells, assessed by a significant decrease of both the Bax/Bcl-2 and Bax/Bcl-xl ratios.


Asunto(s)
Antiinfecciosos/uso terapéutico , Leucocitos Mononucleares/química , Proteína C/uso terapéutico , Choque Séptico , Proteína X Asociada a bcl-2/efectos de los fármacos , Proteína bcl-X/efectos de los fármacos , Adulto , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Antiinfecciosos/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/genética , Femenino , Citometría de Flujo , Expresión Génica/efectos de los fármacos , Humanos , Infusiones Intravenosas , Recuento de Leucocitos , Escala de Lod , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Proteína C/farmacología , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Choque Séptico/sangre , Choque Séptico/tratamiento farmacológico , Proteína X Asociada a bcl-2/análisis , Proteína X Asociada a bcl-2/genética , Proteína bcl-X/análisis , Proteína bcl-X/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA